// App-Quantinova.ai

POS0692 (2021) : IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN’S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL

Researchers

Presenter

  • T. Drner

Principal Investigators

  • S. J. Bowman

  • R. Fox

  • X. Mariette

  • A. Papas

  • T. Grader-Beck

  • B. A. Fisher

  • F. Barcelos

  • S. De Vita

  • H. Schulze-Koops

  • R. J. Moots

  • G. Junge

  • J. Woznicki

  • M. Sopala

  • W. L. Luo

  • W. Hueber

Medical Centers

  • Charite University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany

  • University Hospitals Birmingham NHS Foundation Trust, Department of Rheumatology, Birmingham, United Kingdom

  • University of Birmingham, Birmingham, United Kingdom

  • NIHR Birmingham Biomedical Research Centre, Rheumatology, Birmingham, United Kingdom

  • Scripps Memorial Hospital and Research Institute, Rheumatology, California, United States of America

  • Université Paris- Saclay, Rheumatology, Paris, France

  • Tufts School of Dental Medicine, Division of Oral Medicine, Massachusetts, United States of America

  • John Hopkins University School of Medicine, Division of Rheumatology, Baltimore, United States of America

  • DAME, University Hospital of Udine, Division of Rheumatology, Udine, Italy

  • Ludwig-Maximilians-University of Munich, Division of Rheumatology and Clinical Immunology, Munich, Germany

  • Aintree University Hospital, Academic Rheumatology Department, Liverpool, United Kingdom

  • Edge Hill University, Faculty of Health, Social Care and Medicine, Ormskirk, United Kingdom

  • Novartis Pharma AG, Immunology, Hepatology and Dermatology Development Unit, Basel, Switzerland

Locations

  • Germany

  • United Kingdom

  • United States

  • France

  • Portugal

  • Italy

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Sjogren's syndrome

Biomarkers

  • Telomerase reverse transcriptase

Drug/Treatment

  • VAY736

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • German Research Foundation (Deutsche Forschungsgemeinschaft)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved